指南与共识呼吸衰竭与机械通气

轻度哮喘吸入糖皮质激素起始治疗建议应基于症状频率吗:START 研究的事后疗效分析

Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study.
指南 / 共识 · Lancet · 2016-11-30
一句话结论轻度新发哮喘中,每日一次低剂量布地奈德在各症状频率亚组均降低严重哮喘相关事件风险、减缓肺功能下降并改善症状控制,结果不支持将 ICS 限制在每周症状>2 天的患者。

该研究为 START 研究的事后分析,覆盖 32 个国家、7138 例 4–66 岁轻度哮喘患者,随机接受每日一次吸入布地奈德 400 μg(<11 岁 200 μg)或安慰剂治疗 3 年。按基线症状频率分层后,布地奈德较安慰剂在各亚组均延长至首次严重哮喘相关事件时间(HR 0.54、0.60、0.57,交互 P=0.94),减少需口服或全身糖皮质激素的严重急性发作(率比 0.48、0.56、0.66,交互 P=0.11),并改善支气管舒张前后肺功能及无症状天数。作者结论认为结果不支持将 ICS 限制于每周症状>2 天者,建议轻度哮喘治疗推荐应同时考虑风险降低与症状。

要点

  • 在 0–1 天/周、>1 至≤2 天/周、>2 天/周三个症状频率亚组中,布地奈德较安慰剂均延长至首次严重哮喘相关事件时间(HR 分别为 0.54、0.60、0.57),交互 P=0.94。
  • 布地奈德较安慰剂减少需口服或全身糖皮质激素的严重急性发作,三个亚组率比分别为 0.48、0.56、0.66,交互 P=0.11。
  • 布地奈德较安慰剂在 3 年随访时支气管舒张后肺功能下降更少(交互 P=0.32),支气管舒张前肺功能更高、无症状天数更多(三组均 P<0.0001)。
  • 按任何指南标准分为持续性 vs 间歇性哮喘后结果相似。
  • 作者认为结果不支持将 ICS 限制于每周症状>2 天的患者,轻度哮喘治疗推荐应同时考虑风险降低与症状。

适用人群与场景

  • 4–66 岁、过去 2 年内诊断的轻度哮喘、既往未规律使用糖皮质激素的患者,来自 32 个国家的 START 研究人群。
  • 按基线症状频率分为 0–1 天/周(2184 例,31%)、>1 至≤2 天/周(1914 例,27%)、>2 天/周(3040 例,43%)三个亚组。

处置流程与药物剂量

  • 布地奈德每日一次吸入 400 μg(<11 岁者 200 μg),对照为安慰剂,疗程 3 年,每 3 个月门诊随访一次。

研究设计与关键结果

  • 研究类型为 START 研究的事后疗效分析,共 7138 例(布地奈德 3577 例、安慰剂 3561 例),来自 32 个国家,按意向治疗分析。
  • 至首次严重哮喘相关事件(住院、急诊治疗或死亡)时间:布地奈德 vs 安慰剂在 0–1 天/周亚组 HR 0.54(95%CI 0.34–0.86),>1 至≤2 天/周亚组 HR 0.60(95%CI 0.39–0.93),>2 天/周亚组 HR 0.57(95%CI 0.41–0.79),交互 P=0.94。
  • 需口服或全身糖皮质激素的严重急性发作率比:布地奈德 vs 安慰剂在 0–1 天/周亚组 0.48(95%CI 0.38–0.61),>1 至≤2 天/周亚组 0.56(95%CI 0.44–0.71),>2 天/周亚组 0.66(95%CI 0.55–0.80),交互 P=0.11。
  • 3 年随访时支气管舒张后肺功能下降布地奈德较安慰剂更少(交互 P=0.32);支气管舒张前肺功能更高、无症状天数更多(三个亚组均 P<0.0001),无交互(支气管舒张前交互 P=0.43;无症状天数交互 P=0.53)。
  • 按任何指南标准分为持续性 vs 间歇性哮喘后结果相似。

证据类型、等级与局限

  • 证据类型为随机对照试验(START 研究)的事后分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在轻度新发哮喘中每日一次低剂量布地奈德降低严重哮喘相关事件风险、减缓肺功能下降并改善症状控制,且在各症状频率亚组中效果相似。
  • 作者认为,结果不支持将吸入糖皮质激素限制于每周症状>2 天的患者,轻度哮喘的治疗推荐应同时考虑风险降低与症状。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Low-dose inhaled corticosteroids (ICS) are highly effective for reducing asthma exacerbations and mortality. Conventionally, ICS treatment is recommended for patients with symptoms on more than 2 days per week, but this criterion has scant evidence. We aimed to assess the validity of the previous symptom-based cutoff for starting ICS by establishing whether there was a differential response to budesonide versus placebo for severe asthma exacerbations, lung function, and asthma symptom control across subgroups identified by baseline asthma symptom frequency.

METHODS: We did a post-hoc analysis of the 3 year inhaled Steroid Treatment As Regular Therapy (START) study, done in 32 countries, with clinic visits every 3 months. Patients (aged 4-66 years) with mild asthma diagnosed within the previous 2 years and no previous regular corticosteroids were randomised to receive once daily, inhaled budesonide 400 μg (those aged <11 years 200 μg) or placebo. Coprimary outcomes for this analysis were time to first severe asthma-related event (SARE; hospital admission, emergency treatment, or death) and change from baseline in lung function after bronchodilator. Interaction with baseline symptom frequency was investigated, with patients grouped by more than two symptom days per week and two or fewer symptom days per week (divided into no days to 1 day, and more than 1 day to 2 days). Analysis was done by intention to treat.

FINDINGS: Of 7138 patients (n=3577 budesonide; n=3561 placebo), baseline symptom frequency was 0-1 days per week for 2184 (31%) participants, more than 1 and less than or equal to 2 symptom days per week for 1914 (27%) participants, and more than 2 symptom days per week for 3040 (43%) participants. For budesonide versus placebo, time to first SARE was longer across symptom frequency subgroups (hazard ratios 0·54 [95% CI 0·34-0·86] for 0-1 symptom days per week, 0·60 [0·39-0·93] for >1 to ≤2 symptom days per week, 0·57 [0·41-0·79] >2 symptom days per week, pinteraction=0·94), and the decline in postbronchodilator lung function was less at 3 years' follow-up (pinteraction=0·32). For budesonide versus placebo, severe exacerbations requiring oral or systemic corticosteroids were reduced (rate ratio 0·48 [0·38-0·61] 0-1 symptom days per week, 0·56 [0·44-0·71] >1 to ≤2 symptom days per week, and 0·66 [0·55-0·80] >2 symptom days per week, pinteraction=0·11), prebronchodilator lung function was higher, and symptom-free days were more frequent (p<0·0001 for all three subgroups), with no interaction by symptom frequency (prebronchodilator pinteraction=0·43; symptom-free days pinteraction=0·53). Similar results were noted when participants were classified by any guidelines criterion as so-called persistent versus so-called intermittent asthma.

INTERPRETATION: In mild recent-onset asthma, once daily, low-dose budesonide decreases SARE risk, reduces lung function decline, and improves symptom control similarly across all symptom subgroups. The results do not support restriction of inhaled corticosteroids to patients with symptoms on more than 2 days per week and suggest that treatment recommendations for mild asthma should consider both risk reduction and symptoms.

FUNDING: AstraZeneca.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Reddel HK, Busse WW, Pedersen S, et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet. 2016. PMID: 27912982. doi:10.1016/S0140-6736(16)31399-X

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。